Weekly Report: what happened at IRWD last week (0603-0607)?
Weekly Report · 6d ago
Weekly Report: what happened at IRWD last week (0527-0531)?
Weekly Report · 06/03 09:13
Weekly Report: what happened at IRWD last week (0520-0524)?
Weekly Report · 05/27 09:13
Don't Ignore The Insider Selling In Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. CEO & Director Thomas McCourt recently sold US$436k worth of stock at US$ per share. In the last year, Ironwood pharmaceuticals insiders have sold more than they bought shares for. There has been more insider selling than buying of the company's shares in the last three months. The CEO owns about US$16m of Ironwood Pharmaceutical's shares. But the company does not have a high level of insider ownership.
Simply Wall St · 05/23 10:22
Piper Sandler Sticks to Its Buy Rating for Ironwood Pharma (IRWD)
TipRanks · 05/22 10:35
Ironwood Pharma’s Apraglutide Poised for Market Success: A Strong Buy Recommendation
TipRanks · 05/22 09:16
U.S. RESEARCH ROUNDUP-Ameriprise Financial, Dell Technologies, Stryker
Wall Street securities analysts revise their ratings and price targets on several companies. Ameriprise Financial, Dell Technologies and Stryker among companies with revised targets. Analyst cuts target price to from buy for Bio-Techne Corp, Autozone Inc.  
Reuters · 05/22 07:31
Ironwood Pharma’s Apraglutide Poised for Blockbuster Status with Strong Phase 3 Results: A Buy Rating
Analyst Jason Butler from JMP Securities reiterated a Buy rating on Ironwood Pharma (IRWD – Research Report) and kept the price target at $23. The drug apraglutide has shown significant benefits for patients with Short Bowel Syndrome-Intestinal Failure. Butler anticipates that the drug could achieve blockbuster status.
TipRanks · 05/22 04:25
Reuters · 05/22 03:55
Ironwood Pharmaceuticals’ Growth Potential Bolstered by Promising LINZESS and Apraglutide Clinical Data
TipRanks · 05/21 18:55
Analysts’ Top Healthcare Picks: InfuSystem Holdings, Inc. (INFU), Ironwood Pharma (IRWD)
TipRanks · 05/21 13:10
Ironwood Pharmaceuticals Will Present Late-breaking Data During The 2024 Digestive Disease Week Meeting From Its Phase 3 STARS Trial Of Apraglutide For Short Bowel Syndrome With Intestinal Failure
New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint. Apraglutide achieved enteral autonomy in both stomas and CIC patients. New details on safety and tolerability to be presented.
Benzinga · 05/21 10:13
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals, Inc. Will present late-breaking data from its pivotal Phase III clinical trial, STARS. The study evaluated the efficacy and safety of apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF) The company is working to submit a new drug application to the FDA.
Barchart · 05/21 05:00
Weekly Report: what happened at IRWD last week (0513-0517)?
Weekly Report · 05/20 09:12
Ironwood Pharmaceuticals’ (NASDAQ:IRWD) Challenges Continue with Q1 Misses
TipRanks · 05/14 16:21
Weekly Report: what happened at IRWD last week (0506-0510)?
Weekly Report · 05/13 09:13
Ironwood Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 17:13
Ironwood Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Dow Jones · 05/10 16:37
Ironwood Pharmaceuticals Price Target Cut to $14.00/Share From $18.00 by Craig-Hallum
Dow Jones · 05/10 16:37
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Benzinga · 05/10 16:26
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.